JP2010525025A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525025A5
JP2010525025A5 JP2010504692A JP2010504692A JP2010525025A5 JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5 JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5
Authority
JP
Japan
Prior art keywords
phenyl
compound
pyrimidin
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525025A (ja
JP5566880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/055017 external-priority patent/WO2008129080A1/en
Publication of JP2010525025A publication Critical patent/JP2010525025A/ja
Publication of JP2010525025A5 publication Critical patent/JP2010525025A5/ja
Application granted granted Critical
Publication of JP5566880B2 publication Critical patent/JP5566880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504692A 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体 Expired - Fee Related JP5566880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2007003608 2007-04-24
EPPCT/EP2007/003608 2007-04-24
EP07106951 2007-04-25
EP07106951.2 2007-04-25
PCT/EP2008/055017 WO2008129080A1 (en) 2007-04-24 2008-04-24 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2010525025A JP2010525025A (ja) 2010-07-22
JP2010525025A5 true JP2010525025A5 (enExample) 2011-06-23
JP5566880B2 JP5566880B2 (ja) 2014-08-06

Family

ID=39745232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504692A Expired - Fee Related JP5566880B2 (ja) 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体

Country Status (4)

Country Link
US (2) US8507498B2 (enExample)
EP (1) EP2137166B1 (enExample)
JP (1) JP5566880B2 (enExample)
WO (1) WO2008129080A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
JP5921525B2 (ja) 2010-03-22 2016-05-24 リード ディスカバリー センター ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬的に活性のある二置換のトリアジン誘導体
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
ES2567066T3 (es) * 2011-03-02 2016-04-19 Lead Discovery Center Gmbh Derivados de piridina disustituida farmacéuticamente activos
KR20140019381A (ko) * 2011-04-19 2014-02-14 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 4-아릴-n-페닐-1,3,5-트리아진-2-아민
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
WO2013037894A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CA2848616A1 (en) * 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN104822380B (zh) * 2012-08-23 2019-01-01 维罗斯塔蒂克斯公司 新颖的4,6-二取代的氨基嘧啶衍生物
ES2595222T3 (es) 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
CN105283453B (zh) * 2012-10-18 2018-06-22 拜耳药业股份公司 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物
US20150259300A1 (en) 2012-10-18 2015-09-17 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
US9650340B2 (en) 2012-11-15 2017-05-16 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
ES2622583T3 (es) * 2012-11-15 2017-07-06 Bayer Pharma Aktiengesellschaft 4-(Orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
TW201418243A (zh) * 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
US9770445B2 (en) 2013-07-04 2017-09-26 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
CN105764511B (zh) * 2013-10-04 2019-01-11 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
EP3126338B1 (en) 2014-04-01 2019-09-04 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
EP3126525B1 (en) 2014-04-04 2020-02-19 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
CR20160471A (es) 2014-04-11 2016-12-21 Bayer Pharma AG Compuestos novedosos macrocíclicos
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
EP3207038B1 (en) 2014-10-16 2018-08-22 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
CN107207475A (zh) 2014-10-16 2017-09-26 拜耳医药股份有限公司 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物
CA2980493A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
CA2980507A1 (en) 2015-03-24 2016-09-29 Public University Corporation Nagoya City University Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
ES2902148T3 (es) 2015-06-29 2022-03-25 Astrazeneca Ab Derivados de amidas policíclicas como inhibidores de CDK9
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20180015153A1 (en) 2016-07-16 2018-01-18 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
WO2019075011A1 (en) 2017-10-10 2019-04-18 Florida State University Research Foundation, Inc. EMETIC COMPOUNDS FOR THE TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
KR102764122B1 (ko) 2018-02-13 2025-02-05 바이엘 악티엔게젤샤프트 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
JPWO2020235672A1 (enExample) * 2019-05-23 2020-11-26
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
AU2001242629B2 (en) 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
ES2292753T4 (es) 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20040106647A1 (en) 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
AU2003285007A1 (en) 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
US20070161637A1 (en) 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
CA2553513A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
JP2008542219A (ja) * 2005-05-25 2008-11-27 インゲニウム ファーマシューティカルズ ジーエムビーエイチ 疼痛処置法
JP5693951B2 (ja) * 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
EP2137165B1 (en) * 2007-04-24 2013-04-24 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
JP5566879B2 (ja) * 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤

Similar Documents

Publication Publication Date Title
JP2010525023A5 (enExample)
JP2011502956A5 (enExample)
JP2004536814A5 (enExample)
JP2013523710A5 (enExample)
CN103936680B (zh) 瑞舒伐他汀钙已知杂质的制备方法
RU2013148405A (ru) Ингибиторы киназ
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
RU2006146985A (ru) Модуляторы мускариновых рецепторов
JP2008510763A5 (enExample)
HUT67636A (en) New sulfonylamino-pyrimidines and pharmaceutical compositions containing them
JP2009541268A5 (enExample)
SI2797918T1 (en) Bromodomain inhibitors
IL172567A (en) Trisubstituted aryl and heteroaryl derivatives, pharmaceutical compositions comprising them and their use in the preparation of medicaments for the prophylaxis and treatment of disorders related to metabolism
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2011519854A5 (enExample)
JP2007504160A5 (enExample)
JP2013523803A5 (enExample)
JP2011523646A5 (enExample)
RU2009101911A (ru) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
JP2010520892A (ja) フェニルアミノピリミジン化合物およびその使用
JP2007500179A5 (enExample)
JP2017515836A5 (enExample)
RU2009133846A (ru) Новые производные гидантоина в качестве ингибиторов металлопротеиназ
JP2010513272A5 (enExample)
JP2022548250A5 (enExample)